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Background: Although the outcomes of pancreatic cancer have been improved by gemcitabine, the changes in its
characteristics and long-term outcomes within the gemcitabine era remain unclear. This study was conducted to
identify clinical characteristics of pancreatic cancer patients within the gemcitabine era.
Methods: A retrospective chart review was performed at 10 centers for 1,248 consecutive patients who were ever
considered to have a diagnosis of pancreatic cancer between 2001 and 2010. Data collected included
demographics, diagnosis date, clinical stage, treatment, and outcome; 1,082 patients met the inclusion criteria and
were analyzed further. The chi-square test, Student’s t-test, and Mann–Whitney U-test were used for statistical
analysis. Outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazards regression.
Differences in survival analyses were determined using the log-rank test.
Results: The distribution of clinical stages was: I, 2.2%; II, 3.4%; III, 13%; IVa, 27%; and IVb, 55%. Chemotherapy alone was
administered to 42% of patients and 17% underwent resection. The 1-, 3-, and 5-year survival rates were 39%, 13%, and
6.9%, respectively. The median survival time was 257 days, but differed considerably among treatments and clinical stages.
Demographics, distribution of clinical stage, and cause of death did not differ between groups A (2001–2005, n = 406)
and B (2006–2010, n = 676). However, group B included more patients who underwent chemotherapy (P < 0.0001) and
fewer treated with best supportive care (P = 0.0004), mirroring improvements in this group’s long-term outcomes
(P = 0.0063). Finally, factors associated with long-term outcomes derived from multivariate analysis were clinical stage
(P < 0.0001), location of the tumor (P = 0.0294) and treatments (surgery, chemotherapy) (P < 0.0001).
Conclusions: Long-term outcomes in pancreatic cancer has improved even within the gemcitabine era, suggesting
the importance of offering chemotherapy to patients previously only considered for best supportive care. Most
patients are still diagnosed at an advanced stage, making clinical strategy development for diagnosing pancreatic
cancer at earlier stages essential.
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Pancreatic cancer (PC) has one of the worst prognoses
among cancers worldwide (the overall 5-year survival
rate <5%), and the number of patients with PC is
increasing globally [1]. For example, PC is currently
the fifth leading cause of cancer death in Japan for each sex.
The management of PC has changed since gemicitabine
(GEM) was introduced worldwide in 1996. Nevertheless,
the prognosis for PC remains extremely poor due to a lack
of effective strategies for early detection of the disease [2].
In 2007, the Japanese Pancreas Society (JPS) conducted
a nationwide survey analyzing over 24,000 patients
with PC between 1981 and 2004. The results showed
an improvement in long-term outcomes over the course of
3 different eras (the 1980s, 1990s, and the GEM era [which
for Japan began in 2001]). Improvements in outcome were
largely attributed to an increase in the resection rate
(1980s vs. 90s) and the emergence of GEM (1990s vs.
GEM era) [3]. In addition, using their nationwide PC
registry, the JPS has extended the analysis to include
patients through 2007 (>32,000 cumulative records) and
has confirmed that survival improvements in PC can be
attributed to chemotherapy (primarily GEM) [4]. However,
the changes in the characteristics and outcomes of this
disease in Japan within the GEM era alone have not been
definitively established. Furthermore, guideline compliance
of PC in routine clinical practice is unknown, especially
whether GEM is administered to unresectable PC as
first-line therapy.
In this context, the Ehime Pancreato-Cholangiology
(EPOCH) Study Group was established. This group
conducted a retrospective study to identify the clinical
characteristics of PC in Japan within the GEM era
(after 2001).
Methods
A retrospective chart review was conducted and included
1,248 consecutive patients who were ever considered
to have a diagnosis of PC at the gastroenterology clinic
at Ehime University Hospital or one of its 9 affiliated
hospitals (EPOCH Study Group), between January 2001
and December 2010. As of August 2011, data collected
included demographics (age and sex), date of diagnosis,
tumor location, clinical stage (JPS TNM classification [5]),
treatment, and outcome. Briefly, it must be noted the
difference of TNM classification between JPS and UICC
is in the staging system based on the definition of tumor
factors (T) and lymph node metastases (N). T4 in UICC
indicates tumor invasion limited to the trunk of the celiac
artery or superior mesenteric artery, whereas invasion to
any major vessels, neural plexus, and adjacent organs are
included in the JPS classification. Positive lymph node
metastasis in UICC is N1, while in JPS there exist various
grades depending on the distance from the main tumor(N1, N2, N3). PC was diagnosed on the basis of abdominal
imaging (computed tomography, conventional ultrason-
ography, and magnetic resonance imaging) reported by
radiologists with or without histologic findings (needle
biopsy specimens obtained for suspicion of liver metastasis
obtained under ultrasonography, fine needle aspiration
biopsy specimens obtained under endoscopic ultrasonog-
raphy, or surgical specimens) reported by pathologists.
After an extensive chart review, the final diagnosis
with intraductal papillary mucinous neoplasm (n = 22),
neuroendocrine tumor (n = 5), small cell carcinoma (n = 2),
serous adenocarcinoma (n = 1), and undifferentiated car-
cinoma (n = 1) were excluded from the analysis. Patients
with missing data (n = 135) were also excluded from
the analysis. For patients who did not undergo surgical
resection, the final clinical stage was determined on
imaging. Otherwise, for patients who underwent surgical
resection of the pancreas, the final clinical stage was deter-
mined at the time of pathologic analysis of the surgically
resected specimen. The treatments were divided into 3
categories: surgical resection (with or without adjuvant
chemotherapy), chemotherapy, and best supportive
care (BSC). In total, data from 1,082 patients (87%)
were analyzed. For the purpose of this study, the patients
were divided into 2 groups: Group A (2001–2005, n = 406)
and Group B (2006–2010, n = 676). Since only a small
number of patients received radiation therapy and its
proportion did not differ between Group A (n = 36, 8.9%)
and Group B (n = 45, 6.7%) (P = 0.1810), these patients
were included in the treatment groups corresponding to
their main treatment: surgical resection (n = 10), chemo-
therapy (n = 63), and BSC (n = 8).
The chi-square test, Student’s t-test, and Mann–Whitney
U-test were used for statistical analysis, where appropriate.
Outcomes were analyzed using the Kaplan-Meier method
and Cox proportional hazards regression. Differences in
survival analyses were determined using the log-rank
test. Two-tailed significance was defined in all analyses as
a P-value < 0.05. All statistical analyses were performed
using a statistical software package (JMP, version 8; SAS
Institute, Cary, NC). Data were stored in a secure database
and patients were numerically coded to anonymize data.
The study protocol conformed to the ethical guidelines of
the 1975 Declaration of Helsinki and was approved by the
local ethics committee at the Ehime University Graduate
School of Medicine.
Results
Demographic features of the entire cohort
The mean ± standard deviation for the age of male subjects
included in the cohort was 69 ± 11 years (range, 33–91 years,
n = 566) and 74 ± 11 years (range, 37–86 years, n = 516)
for female subjects. The female subjects were significantly
older than the male subjects (P < 0.0001). The distribution
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(n = 37, 3.4%), III (n = 141, 13%), IVa (n = 288, 27%), and
IVb (n = 594, 55%). This distribution did not change
significantly over time: Stage I, 0–3.8%; Stage II, 0–6%;
Stage III, 6.6–19%; Stage IVa, 23–33%; and Stage IVb,
50–59% (Figure 1a). The mean age of patients did not
differ among clinical stages: 75 ± 13 years, 73 ± 11 years,
71 ± 11 years, 72 ± 11 years, and 71 ± 11 years for Stages
I, II, III, IVa, and IVb, respectively. Tumors were located
mostly in the head of the pancreas (n = 634, 59%),
followed by the body (n = 235, 22%) and the tail (n = 130,
12%) of the pancreas. The association between clinical
stage and tumor location was analyzed in 999 patients
(92.3%) after 83 patients who had tumors that were either
difficult to locate (n = 34, 3.1%) or that had expanded to
multiple sites (n = 49, 4.5%) were excluded. Stage IVb






















































Figure 1 Changes in the clinical stages and treatments in pancreatic
cancer between 2001 and 2010 (n = 1,082). b. Changes in treatments for pa
operation; CT, chemotherapy; RT, radiation therapy; BSC, best supportive cahead of the pancreas (P < 0.0001), whereas more patients
with Stage IVb cancer had tumors in the tail of the
pancreas than patients who did not have Stage IVb
disease: Stage IVb (n = 529; tumor location: head 54%,
n = 284; tumor location: body 26%, n = 137; tumor
location: tail 20%, n = 108) vs. non-Stage IVb disease
(n = 470; tumor location: head 75%, n = 350; tumor loca-
tion: body 21%, n = 98; tumor location: tail 4.7%, n = 22).
Treatments for the entire cohort
From the entire cohort, 42% (9%, 8%, 16%, 35%, and 46%
of the patients in Stages I, II, III, IVa, and IVb, respectively)
underwent chemotherapy alone (GEM-based, 88%) and
the number of patients receiving chemotherapy increased
over time (Figure 1b). GEM was chosen as a first-line
regimen in 81% of the patients, followed by S-1 (12%)






























cancer. a. Changes in the clinical stages of patients with pancreatic
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Figure 2 Comparison of survival curves in pancreatic cancer.
a. Comparison of survival curves among clinical stages in patients
with pancreatic cancer (n = 1,082). MST, median survival time.
b. Comparison of survival curves among different treatments in
patients with pancreatic cancer (n = 1,082). MST, median survival
time; OP, operation; CT, chemotherapy; BSC, best supportive care.
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and 3.5% of the patients in Stages I, II, III, IVa, and IVb,
respectively), and adjuvant chemotherapy was given to
53% (n = 100) of these patients. Notably, 11 patients
(50%) and 11 patients (30%) in Stages I and II, respectively,
chose BSC. The primary reasons for this choice were:
patient and family preference (n = 6), advanced age (n = 3),
poor performance status (n = 3), serious complications
(n = 2), and unknown (n = 8).
Long-term outcomes for the entire cohort
During the mean observation period of 288 ± 374 days
(range, 1–3052 days; median, 176 days), 685 patients
died. The cause of death was identified in 629 patients
(92%) and was related to PC in 95.1% (n = 598). Only 4.9%
(n = 31) of deaths were unrelated to PC (i.e., pneumonia,
n = 4; cardiac disease, n = 4; upper gastrointestinal
hemorrhage, n = 2; other, n = 21). Overall, the 1-, 3-, and 5-
year survival rates were 39%, 13%, and 6.9%, respectively.
The median survival time (MST) of the entire cohort was
257 days but differed significantly among clinical stages
(474 days, 599 days, 822 days, 324 days, and 162 days
for Stages I, II, III, IVa, and IVb, respectively; P < 0.0001
between Stages III and IVa and between Stages IVa and
IVb; Figure 2a). Significant differences were also found
in MST with respect to tumor location (MST for tumors
involving the head of the pancreas, 287 days; MST for
tumors not involving the head, 230 days; P < 0.0001)
and with respect to treatments (831 days, 265 days, and
86 days for resection, chemotherapy, and BSC, respectively;
P < 0.0001; Figure 2b).
Analysis comparing the 2 groups (Group A and Group
B) did not show any significant differences in demographics
(age and sex), distribution of clinical stage, and cause of
death (PC-related vs. PC-unrelated). Although the resection
rate did not differ between Group A and Group B (16% vs.
18%; P = 0.306), Group B (n = 148) included more patients
with Stage III disease (46% vs. 36% in group A) and
fewer with Stage IVa disease (28% vs. 45% in Group A;
P = 0.012). Group B also included more patients treated
with chemotherapy and fewer with BSC than Group A
(chemotherapy, 51% vs. 42%; P < 0.0001, BSC, 31% vs.
42%; P = 0.0004) (Table 1).
The long-term outcome of Group B was significantly
better than that of Group A (MST: Group A, 229 days
vs. Group B, 280 days; P = 0.0063; Figure 3a). The entire
unresected group, patients who chose chemotherapy or
BSC, significantly improved its long-term outcome
(N = 895) (MST: Group A, 181 days vs. Group B, 224 days;
P = 0.0063; Figure 3b). Sub-analyses also showed a signifi-
cant improvement in the 2 groups when chemotherapy
was given (MST in Group A: chemotherapy, 264 days vs.
BSC, 82 days; P < 0.0001; Figure 3c) (MST in Group B:
chemotherapy, 299 days vs. BSC, 86 days; P < 0.0001;Figure 3d). However, long-term outcomes did not differ
statistically between the 2 groups when compared separ-
ately with respect to chemotherapy (MST: Group A,
264 days vs. Group B, 299 days; P = 0.5476) and BSC
(MST: Group A, 82 days vs. Group B, 86 days; P = 0.3949).
On the other hand, the surgically resected group did not
improve its long-term outcome (N = 187) (MST: Group
A, 705 days vs. Group B, 1019 days; P = 0.2338; Figure 3e).
Although Group B also contained more patients who
received adjuvant chemotherapy compared to Group A
(61% vs. 38%: P = 0.0023), long-term outcomes for Group
A (MST: with adjuvant chemotherapy, 749 days vs.
without adjuvant chemotherapy, 532 days; P = 0.5037),
and Group B (MST: with adjuvant chemotherapy, 438 days
vs. without adjuvant chemotherapy, 273 days; P = 0.2271)
Table 1 Comparison of the baseline demographics between 2001–2005 and 2006–2010 in patients with pancreatic
cancer (n = 1,082)
Total 2001–2005 2006–2010 P-value
Age (y) 71.5 ± 10.9 71.0 ± 10.4 71.8 ± 11.2 0.24911
Sex (Male/Female) 566/516 210/196 356/320 0.76472
Stage I 22 (2.0%) 10 (2.5%) 12 (1.8%) 0.43762
II 37 (3.4%) 13 (3.2%) 24 (3.6%) 0.76022
III 141 (13.0%) 46 (11.3%) 95 (14.0%) 0.19762
IVa 288 (26.6%) 113 (27.8%) 175 (25.9%) 0.48342
IVb 594 (54.9%) 224 (55.2%) 370 (54.7%) 0.88832
Treatment Surgery 187 (17.3%) 64 (15.8%) 123 (18.2%) 0.30572
Chemotherapy 519 (48.0%) 172 (42.4%) 347 (51.3%) <0.00012
BSC/RT 376 (34.8%) 170 (41.9%) 206 (30.5%) 0.00042
Cause of death 654/31 274/12 380/19 0.72522
PC related/PC unrelated
BSC, best supportive care; RT, radiation therapy; PC, pancreatic cancer.
1Student’s t-test; 2chi square test.
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chemotherapy and those who did not. Additional analysis
evaluating a benefit of adjuvant chemotherapy among
different clinical stage groups (stage I - III, stage IVa)
failed to show its benefit over surgery alone: stage I - III
(P = 0.1335) and stage IVa (P = 0.2424).Factors associated with long-term outcomes
Finally, the factors associated with long-term outcomes
in the 1,082 patients with PC were analyzed. According
to univariate analysis, variables significantly associated
with better survival were younger age (HR 0.80; 95% CI,
0.67 – 0.94; P = 0.0072), earlier stages (stage I – III vs. stage
IVa - IVb: HR 0.32; 95% CI, 0.25 – 0.40; P < 0.0001), tumor
location (head vs. non-head: HR 0.77; 95% CI, 0.66 – 0.91;
P = 0.0015), treatments [(surgery vs. chemotherapy: HR
0.31; 95% CI, 0.24 – 0.40; P < 0.0001), (surgery vs. BSC:
HR 0.11; 95% CI, 0.08 – 0.14; P < 0.0001), (chemotherapy
vs. BSC: HR 0.34; 95% CI, 0.29 – 0.40; P < 0.0001)],
and the period diagnosed as PC (Group B vs. Group
A: HR 0.81; 95% CI, 0.69 – 0.94; P = 0.0063) (Table 2).
Furthermore, multivariate analysis showed that earlier
stages (stage I – III vs. stage IVa - IVb: HR 0.46; 95%
CI, 0.36 – 0.59; P < 0.0001), tumor location (head vs.
non-head: HR 0.83; 95% CI, 0.71 – 0.98; P = 0.0294), and
treatments [(surgery vs. chemotherapy: HR 0.43; 95%
CI, 0.33 – 0.56; P < 0.0001), (surgery vs. BSC: HR 0.13;
95% CI, 0.10 – 0.18; P < 0.0001), (chemotherapy vs.
BSC: HR 0.31 95% CI, 0.26 – 0.37; P < 0.0001)] were
significantly associated with long-term outcomes (Table 2).
However, age (P = 0.4581) and the period diagnosed
as PC (P = 0.2357) did not associate with long-term
outcomes.Discussion
This multicenter retrospective study performed in gastro-
enterology clinics (EPOCH Study Group) in Japan, reports
findings for 1,082 patients with PC. The results of this
study support previously reported findings in that (1) a
vast majority of patients with PC are still diagnosed at
advanced stages; (2) patient prognosis in PC remains
extremely poor; (3) tumors located in the pancreatic head
are encountered most often at diagnosis; (4) tumors
located in the tail are more often diagnosed at Stage
IVb; (5) patients with PC involving the pancreatic head
have a better prognosis than those with tumors in the
body or tail; and (6) very few patients with PC may expect
long-term survival, unless diagnosed at an earlier stage
and treated with surgical resection. More importantly, this
study was the first to observe and identify changes in the
clinical characteristics of PC in a large number of patients
within the GEM era.
Overall, this study showed an improvement in long-term
outcomes within the GEM era, and the associated factors
for were clinical stage, tumor location and treatments
(surgery and chemotherapy). The former finding is likely
to be related to more patients being given an opportunity
to undergo chemotherapy (the majority with a GEM-based
regimen as first-line treatment) and fewer patients choosing
BSC in the second half of the study period. Although not
investigated, this was presumably due to physician’s skill
up in chemotherapy rather than the change of patient
characteristics, and indeed the referral pattern did not
change during the study period. The improvement in MST
differed by only 51 days between Group A (2001–2005)
and Group B (2006–2010). However, considering that MST
in Group A was as short as 229 days and PC is associated
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Figure 3 Comparison of survival curves in pancreatic cancer. a. Comparison of survival curves between Group A (2001–2005) and Group B
(2006–2010) in patients with pancreatic cancer (n = 1,082). MST, median survival time. b. Comparison of survival curves between Group A
(2001–2005) and Group B (2006–2010) in patients with pancreatic cancer who chose chemotherapy or best supportive care (n = 895). MST,
median survival time. c. Comparison of survival curves between patients with pancreatic cancer who chose chemotherapy and best supportive
care in Group A (2001–2005) (n = 342). MST, median survival time. d. Comparison of survival curves between patients with pancreatic cancer who
chose chemotherapy and best supportive care in Group B (2006–2010) (n = 553). MST, median survival time. e. Comparison of survival curves
between Group A (2001–2005) and Group B (2006–2010) in patients who had pancreatic cancer and underwent surgical resection (n = 187). MST,
median survival time.
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Table 2 Factors associated with long-term outcomes
pancreatic cancer derived from univariate analysis and
multivariate analysis (n = 1,082)
Hazard ratio 95% CI P-value
Univariate analysis
Age < 65 years old 0.80 0.67 ‐ 0.94 0.0072
Female 0.95 0.82 ‐ 1.11 0.5648
Surgery (vs. Chemotherapy) 0.31 0.24 ‐ 0.40 <0.0001
Surgery (vs. BSC) 0.11 0.08 ‐ 0.14 <0.0001
Chemotherapy (vs. BSC) 0.34 0.29 ‐ 0.40 <0.0001
Tumor Location (Head) 0.77 0.66 ‐ 0.91 0.0015
Group B (2006–2010) 0.81 0.69 ‐ 0.94 0.0063
Stage I‐III 0.32 0.25 ‐ 0.40 <0.0001
Multivariate analysis
Age < 65 years old 0.94 0.79 ‐ 1.11 0.4581
Surgery (vs. Chemotherapy) 0.43 0.33 ‐ 0.56 <0.0001
Surgery (vs. BSC) 0.13 0.10 ‐ 0.18 <0.0001
Chemotherapy (vs. BSC) 0.31 0.26 ‐ 0.37 <0.0001
Tumor Location (Head) 0.83 0.71 ‐ 0.98 0.0294
Group B (2006–2010) 0.91 0.78 ‐ 1.06 0.2357
Stage I‐III 0.46 0.36 ‐ 0.59 <0.0001
BSC, best supportive care.
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the treatment of PC. Significant improvement in long-term
outcomes was not seen over time (Group A vs. Group B)
for chemotherapy (MST, 264 vs. 299 days). However,
patients who were given chemotherapy had significantly
better long-term outcomes than those who chose BSC
in the 2 groups. Significant improvement in long-term
outcomes was also not seen over time for surgical resection
(MST, 705 vs. 1019 days). This may be due to a small
number of patients for surgical resection in our study
population among gastroenterology clinics. Notably, more
than 20% of patients with PC still chose BSC. In general,
quality of life (QOL) is one of the most important factors
when patients are considering chemotherapy as a treatment
option, but this study did not investigate QOL data.
Therefore, this study cannot evaluate changes in QOL
with either chemotherapy or BSC. Nevertheless, a linear
increase in the number of patients choosing chemother-
apy and a concomitant decrease in patients choosing BSC
were seen (Figure 1b).
The cohort included in this study was unique because
11 patients (50%) in Stage I and 11 patients (30%) in Stage
II chose BSC, which led to a poorer prognosis associated
with these stages. This observation was likely due to referral
patterns in this retrospective study conducted among
gastroenterology clinics (i.e., these patients were not
referred to surgeons but directly to gastroenterologists).
The results of this study could not help identify the
precise reasons in all patients in Stages I and II whodid not undergo resection or chemotherapy. Previous
studies have clearly shown that surgical resection improves
prognosis among patients with locally advanced PC [6,7].
However, only a few studies have investigated the benefits
of surgery among elderly patients and none of these studies
were large. Therefore, the ability to extrapolate these data
to an elderly population remains controversial [8]. It is
also important to identify the role of chemotherapy in the
elderly. Yamagishi, et al. showed that elderly patients
(>75 years of age) who had good performance status and
were treated with GEM had significantly better long-term
outcomes without serious adverse events than those who
did not receive any treatment [9]. However, like the
current study, this study was retrospective. A prospective
study is necessary to identify the true impact of chemo-
therapy in elderly patients with PC. This suggests that in
order to further improve long-term outcomes in PC, it
is important to offer treatment to patients who were
previously only considered for BSC. Some reports have
claimed that other types of cancer are undertreated in
elderly patients because of clinician preference and patient
bias [10-12]. Therefore, it is important to provide accurate
information about treatments for PC, especially to elderly
patients.
The strengths of this study include a large number of
consecutive patients, the inclusion of gastroenterology
clinics located in teaching, academic, and community
hospitals, and an observation period limited to the GEM
era. All of these strengths support generalization of these
findings as they represent the current state of routine
healthcare service. Also our patients were much older
than the previous national study (age; 64 vs. 69 in men,
66 vs. 74 in women) [3]. This may foresee our future
clinical practice in entire Japan where aging is becoming
an issue. In contrast, as with all retrospective studies,
the results of this study must be viewed in light of the
limitations. Since the principle aim of this study was to
identify the broad picture of changes in the clinical
characteristics of PC within the GEM era, other detailed
data (e.g., performance status, family history, medical
history, associated diseases, presentation pattern, and
laboratory tests including biochemical, tumor markers,
and histology) were not collected. Most importantly, we
assumed that not all patients had histologically-proven
adenocarcinoma, which may change the treatment strategy
and prognosis. Additionally, even with a small number of
patients, we might have included non-malignant cases.
However, these possible cases are usually a candidate for
surgical resection and given a final histological diagnosis.
Indeed, histologic examination was studied in only 54.5%
of patients, even in a nationwide analysis conducted by
JPS [3]. Nevertheless, given that the vast majority (87%) of
those Japanese patients with PC who underwent histologic
examination were diagnosed with adenocarcinoma [3],
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and prognosis in the current study population as well.
In this regard, fine needle aspiration biopsy in the future
may play a cardinal role for patients (those undergoing
chemotherapy in particular), despite the fact that this
procedure was performed at very few institutes until its
nationwide approval in Japan in 2011. Additionally, one
may argue that data related to the details of the chemother-
apy regimens were not included (e.g., treatment response,
adverse effects, and QOL during treatment). Therefore,
it will be important to obtain these data when future
prospective studies are conducted to further investigate
clinical features that may change the management and
eventually the prognosis of PC.
Although a significant improvement in the long-term
outcomes of PC was achieved over the decade included
in this study, it is important to stress that the clinical
stage at diagnosis did not change over the same period
(Figure 1a). As reported previously [3], Stages I and
II represented only 5.6% of the patients presenting
throughout the observation period. An effective clinical
strategy for the diagnosis of PC at earlier stages is urgently
required and several screening programs have been
attempted, especially among individuals with a family
history of PC [10,11]. However, to date, no program has
been shown to effectively identify patients with PC at
earlier stages [13,14].Conclusions
This study showed that long-term outcomes in pancreatic
cancer have improved even within the GEM era. These
results suggest the importance of offering chemotherapy to
patients previously only considered for BSC. Nevertheless,
the vast majority of patients are still diagnosed at an
advanced stage, making an effective clinical strategy for
the diagnosis of PC at earlier stages a crucial requirement.
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